Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
EAST RUTHERFORD, N.J., April 19, 2018 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced a commitment to provide its stockholders with additional information regarding its environmental, social and governance (ESG) practices. Cambrex’s commitment to the environment, health and safety underpins our activities across our sites. Over approximately the next 18 to 24 months, Cambrex will develop additional disclosures relating to our ESG related policies, strategies and performance. Once available, stockholders will be able to review these disclosures on Cambrex’s website at www.cambrex.com. In connection with today’s announcement, Trillium Asset Management, LLC informed Cambrex that it has withdrawn its shareholder proposal requesting the production of an ESG report from the agenda for the upcoming 2018 Annual Meeting of Stockholders. Cambrex has appreciated Trillium’s perspective on ESG matters and the feedback we received from our investors as part of our shareholder outreach effort.
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and continuous processing. For more information, please visit www.cambrex.com.
Contact:
Tom Vadaketh
Executive VP & CFO
Tel: +201 804 3033
Email: [email protected]
